PSMA PET radiotracer agent development emphasized small urea-based PSMA ligands which target PSMA’s extracellular active substrate recognition sites with high binding affinity to PCa cells, thus, showing rapid plasma clearance and high tumor-background ratios [42]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.